Ronnie Willenheimer

Malmoe, M, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial.

Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial.

Journal: JAMA cardiology

Published: February 16, 2022

Frequency and Impact of Hyponatremia on All-Cause Mortality in Patients With Aortic Stenosis.

Frequency and Impact of Hyponatremia on All-Cause Mortality in Patients With Aortic Stenosis.

Journal: The American journal of cardiology

Published: August 20, 2020

The Association between Serum Testosterone and Risk Factors for Atherosclerosis.

The Association between Serum Testosterone and Risk Factors for Atherosclerosis.

Journal: Current urology

Published: December 16, 2018

Association between serum levels of testosterone and biomarkers of subclinical atherosclerosis.

Association between serum levels of testosterone and biomarkers of subclinical atherosclerosis.

Journal: The aging male : the official journal of the International Society for the Study of the Aging Male

Published: December 24, 2017

Association Between Erectile Function and Biomarkers of Subclinical Atherosclerosis: A Study Based on Middle-Aged Healthy Men from the General Population.

Association Between Erectile Function and Biomarkers of Subclinical Atherosclerosis: A Study Based on Middle-Aged Healthy Men from the General Population.

Journal: Current urology

Published: July 08, 2015

Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS).

Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS).

Journal: Circulation

Published: July 02, 2015

High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy.

High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy.

Journal: Open heart

Published: May 27, 2014

Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.

Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.

Journal: The American journal of cardiology

Published: May 22, 2014

Adjusting parameters of aortic valve stenosis severity by body size.

Adjusting parameters of aortic valve stenosis severity by body size.

Journal: Heart (British Cardiac Society)

Published: May 01, 2014

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.

Journal: European journal of heart failure

Published: March 14, 2014

Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).

Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).

Journal: PloS one

Published: January 24, 2014

Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis.

Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis.

Journal: Heart (British Cardiac Society)

Published: August 24, 2013

Showing 1-12 of 20

Last Updated: 09/26/2026